Vireo Growth Inc. Announces Multiple Ohio Acquisitions (stock‑only)

What Happened
Vireo Growth Inc. (VREOF) filed an 8‑K (filed Aug 5, 2026) disclosing that on July 30, 2026 it signed securities purchase agreements to acquire four Ohio cannabis businesses: FarmaceuticalRx LLC (FRX), FarmaceuticalRX2 LLC (FRX2), Canoe Hill Ohio, LLC (Canoe Hill) and CAOH LLC (CAOH). All deals are structured as stock‑only transactions payable in Vireo subordinate voting shares, closing subject to customary conditions and regulatory approvals. A press release about the transactions was issued July 31, 2026.

Key Details

• FRX: estimated closing purchase price ≈ $139.5M; initial tranche priced at $18.75/share; ~7,440,533 shares estimated for closing (before escrow). CACO convertible notes of ≈ $12.7M will be converted into membership interests pre‑closing.
• FRX2: Closing EBITDA $12.3M; base EBITDA consideration ≈ $70.1M but after assumed indebtedness and adjustments estimated closing purchase price ≈ $19.2M; initial closing shares estimated ≈ 1,023,130 (before escrow). A CACO convertible note (max $10.8M) must convert prior to closing.
• Canoe Hill / CAOH: Canoe Hill base EBITDA consideration $34.8M (Closing EBITDA $6.1M); CAOH base EBITDA consideration $16.0M (Closing EBITDA $2.8M). All deals use a 50%/25%/25% share payment schedule (closing / 90 days / 180 days) with deferred tranches priced at the greater of $17.25 or the 20‑day VWAP; initial tranches locked up through Dec 31, 2026 and later tranches into March 31, 2028.
• Escrow & clawbacks: 10% of closing shares held in escrow for 24 months. Each agreement includes a performance‑based forfeiture (clawback) up to 25% of issued shares if (i) 2027 EBITDA drops >3.5% vs. closing EBITDA, (ii) 2027 EBITDA margin < 2025 margin, and (iii) Vireo’s 20‑day average share price > $31.50.
• Related‑party and ownership limits: CEO John Mazarakis is an equity participant in CAOH and an affiliate partner of Chicago Atlantic; under the CAOH deal Mazarakis would receive 421,344 shares (increasing his holdings from 327,791 to 749,135). Chicago Atlantic affiliates are secured lenders to the targets and post‑closing must collectively hold <20% of Vireo’s subordinate voting shares (otherwise shareholder approval may be required under the exchange rules).

Why It Matters
These transactions materially expand Vireo’s Ohio footprint through four acquisitions paid entirely in shares, which conserves cash but will dilute existing shareholders. The deals include sizeable estimated purchase values (notably FRX at ≈$139.5M) and contingent adjustments/forfeitures tied to 2027 performance, so final share issuances may change. Related‑party involvement (CEO’s interest in CAOH and ties to Chicago Atlantic/CACO) and convertible‑note conversions are highlighted and subject to disclosure and governance requirements. Investors should note regulatory approvals, potential concentration of ownership by Chicago Atlantic affiliates, and escrow/lock‑up periods that restrict resale of issued shares.